Description
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE effective January 1, 2026, issued through preferential allotment via warrant conversion.
Summary
BSE has listed 16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED (Scrip Code: 536565) effective from January 1, 2026. These shares were issued at Rs. 20/- per share (face value Rs. 10/- plus premium of Rs. 10/-) to Promoter and Non-Promoter on a preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.
Key Points
- Total new shares listed: 16,61,000 equity shares of Rs. 10/- each
- Issue price: Rs. 20/- per share (including Rs. 10/- premium)
- Allotment date: October 23, 2025
- Trading commencement: January 1, 2026
- Distinctive numbers: 14480001 to 16141000
- ISIN: INE314I01036
- Shares rank pari-passu with existing equity shares
- Issued on preferential basis through warrant conversion
Regulatory Changes
No regulatory changes introduced. This is a standard listing notification.
Compliance Requirements
Trading members must note the listing of these new securities for trading purposes effective January 1, 2026.
Important Dates
- Allotment Date: October 23, 2025
- Trading Start Date: January 1, 2026
- Lock-in Expiry (11,25,000 shares): July 31, 2027
- Lock-in Expiry (5,36,000 shares): July 31, 2026
Lock-in Details
- 11,25,000 shares (Dist. Nos. 14480001 to 15605000) locked in until July 31, 2027
- 5,36,000 shares (Dist. Nos. 15605001 to 16141000) locked in until July 31, 2026
Impact Assessment
Limited impact on broader market. This is a company-specific corporate action involving preferential allotment to promoters and non-promoters. The lock-in periods indicate regulatory compliance for preferential issues. The new shares represent capital raised through warrant conversion, potentially strengthening the company’s equity base.
Impact Justification
Routine listing of new securities for a single company through preferential allotment. Limited market-wide impact.